Switch theme
Sign up to access all valuation multiples
Akeso Inc is an investment holding company. The Company’s subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China, and also has its presence in USA and Other regions.
2019
3.0K+
LTM Revenue $413M
LTM EBITDA -$13.3M
$9.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Akeso has a last 12-month revenue (LTM) of $413M and a last 12-month EBITDA of -$13.3M.
In the most recent fiscal year, Akeso achieved revenue of $271M and an EBITDA of -$30.5M.
Akeso expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Akeso valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $413M | XXX | $271M | XXX | XXX | XXX |
| Gross Profit | $360M | XXX | $234M | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$13.3M | XXX | -$30.5M | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -11% | XXX | XXX | XXX |
| EBIT | -$40.9M | XXX | -$64.3M | XXX | XXX | XXX |
| EBIT Margin | -10% | XXX | -24% | XXX | XXX | XXX |
| Net Profit | -$40.4M | XXX | -$65.7M | XXX | XXX | XXX |
| Net Margin | -10% | XXX | -24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Akeso's stock price is HKD 84 (or $11).
Akeso has current market cap of HKD 75.2B (or $9.6B), and EV of HKD 71.6B (or $9.1B).
See Akeso trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $9.1B | $9.6B | XXX | XXX | XXX | XXX | $-0.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Akeso has market cap of $9.6B and EV of $9.1B.
Akeso's trades at 33.7x EV/Revenue multiple, and -299.6x EV/EBITDA.
Equity research analysts estimate Akeso's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Akeso has a P/E ratio of -258.7x.
See valuation multiples for Akeso and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $9.6B | XXX | $9.6B | XXX | XXX | XXX |
| EV (current) | $9.1B | XXX | $9.1B | XXX | XXX | XXX |
| EV/Revenue | 24.1x | XXX | 33.7x | XXX | XXX | XXX |
| EV/EBITDA | -747.5x | XXX | -299.6x | XXX | XXX | XXX |
| EV/EBIT | -243.0x | XXX | -142.0x | XXX | XXX | XXX |
| EV/Gross Profit | 27.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -258.7x | XXX | -146.2x | XXX | XXX | XXX |
| EV/FCF | -485.2x | XXX | -63.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAkeso's last 12 month revenue growth is 63%
Akeso's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Akeso's rule of 40 is 111% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Akeso's rule of X is 153% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Akeso and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 63% | XXX | 69% | XXX | XXX | XXX |
| EBITDA Margin | -3% | XXX | -11% | XXX | XXX | XXX |
| EBITDA Growth | -893% | XXX | -61% | XXX | XXX | XXX |
| Rule of 40 | 111% | XXX | 51% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 153% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 47% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 110% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Akeso acquired XXX companies to date.
Last acquisition by Akeso was XXXXXXXX, XXXXX XXXXX XXXXXX . Akeso acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Akeso founded? | Akeso was founded in 2019. |
| Where is Akeso headquartered? | Akeso is headquartered in Hong Kong. |
| How many employees does Akeso have? | As of today, Akeso has 3.0K+ employees. |
| Who is the CEO of Akeso? | Akeso's CEO is Dr. Yu Xia. |
| Is Akeso publicy listed? | Yes, Akeso is a public company listed on HKG. |
| What is the stock symbol of Akeso? | Akeso trades under 09926 ticker. |
| When did Akeso go public? | Akeso went public in 2020. |
| Who are competitors of Akeso? | Similar companies to Akeso include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Akeso? | Akeso's current market cap is $9.6B |
| What is the current revenue of Akeso? | Akeso's last 12 months revenue is $413M. |
| What is the current revenue growth of Akeso? | Akeso revenue growth (NTM/LTM) is 63%. |
| What is the current EV/Revenue multiple of Akeso? | Current revenue multiple of Akeso is 24.1x. |
| Is Akeso profitable? | Yes, Akeso is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Akeso? | Akeso's last 12 months EBITDA is -$13.3M. |
| What is Akeso's EBITDA margin? | Akeso's last 12 months EBITDA margin is -3%. |
| What is the current EV/EBITDA multiple of Akeso? | Current EBITDA multiple of Akeso is -747.5x. |
| What is the current FCF of Akeso? | Akeso's last 12 months FCF is -$20.5M. |
| What is Akeso's FCF margin? | Akeso's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of Akeso? | Current FCF multiple of Akeso is -485.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
